(Q38069580)

28 August 2017

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD (English)

1 reference

28 August 2017

Charlotte Suppli Ulrik

series ordinal

1

object named as

Charlotte Suppli Ulrik

1 reference

28 August 2017

14 December 2012

1 reference

The open respiratory medicine journal

28 August 2017

1 reference

28 August 2017

6

1 reference

28 August 2017

150-154

1 reference

A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients

28 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Clinical practice. Outpatient management of severe COPD.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

The role of anticholinergics in chronic obstructive pulmonary disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Aclidinium bromide provides long-acting bronchodilation in patients with COPD.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3527890

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

31 August 2018

1 reference

12 December 2020

Effect of indacaterol on exercise endurance and lung hyperinflation in COPD

1 reference

12 December 2020

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD

1 reference

12 December 2020

Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting β(2)-agonist remains unclear

1 reference

12 December 2020

10.2174/1874306401206010150

Identifiers

DOI

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

PMCID

3527890